BI Selects OgilvyHealth for Global Pradaxa Brief
Charting the future of public relations
Holmes Report
CEO

BI Selects OgilvyHealth for Global Pradaxa Brief

Following a competitive pitch process, Boehringer Ingelheim has appointed OgilvyHealthPR as its global communications agency for Pradaxa, one of a new generation of oral anticoagulants.

Paul Holmes

LONDON—Following a competitive pitch process,  Boehringer Ingelheim has appointed OgilvyHealthPR as its global communications agency for Pradaxa, one of a new generation of oral anticoagulants targeting an unmet medical need in the prevention and treatment of acute and chronic thromboembolic disease.

 

The account will be led by Deanne Wallace, business unit head, based in London. OgilvyHealthPR will be working in partnership with sister company Ogilvy Healthworld Digital, headed up by managing partners Caroline Howe and David Davenport-Firth, to develop and implement an integrated communications programme.


OgilvyHealthPR and
Boehringer Ingelheim have a longstanding relationship and are already working together on global communications for many of the company’s brands.

View Style:

Load 3 More
comments powered by Disqus